Sistema de Salut de Catalunya
Institut Català de la Salut
[Loscertales J] Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain. [Abrisqueta-Costa P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gutierrez A] Hematology Department, Hospital Son Espases/IdISBa, Palma de Mallorca, Spain. [Hernández-Rivas JÁ] Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain. [Andreu-Lapiedra R] Hematology Department, Hospital Universitario La Fe, Valencia, Spain. [Mora A] Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-09-01T07:28:38Z
2023-09-01T07:28:38Z
2023-08-10
Artificial intelligence; Chronic lymphocytic leukemia; Natural language processing
Inteligencia artificial; Leucemia linfocítica crónica; Procesamiento del lenguaje natural
Intel·ligència artificial; Leucèmia limfocítica crònica; Processament del llenguatge natural
The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) from seven Spanish hospitals (January 2016–December 2018) were analyzed using EHRead® technology, based on NLP and machine learning. A total of 534 CLL patients were assessed. No treatment was detected in 270 (50.6%) patients (watch-and-wait, W&W). First-line (1L) treatment was identified in 230 (43.1%) patients and relapsed/refractory (2L) treatment was identified in 58 (10.9%). The median age ranged from 71 to 75 years, with a uniform male predominance (54.8–63.8%). The main comorbidities included hypertension (W&W: 35.6%; 1L: 38.3%; 2L: 39.7%), diabetes mellitus (W&W: 24.4%; 1L: 24.3%; 2L: 31%), cardiac arrhythmia (W&W: 16.7%; 1L: 17.8%; 2L: 17.2%), heart failure (W&W 16.3%, 1L 17.4%, 2L 17.2%), and dyslipidemia (W&W: 13.7%; 1L: 18.7%; 2L: 19.0%). The most common antineoplastic treatment was ibrutinib in 1L (64.8%) and 2L (62.1%), followed by bendamustine + rituximab (12.6%), obinutuzumab + chlorambucil (5.2%), rituximab + chlorambucil (4.8%), and idelalisib + rituximab (3.9%) in 1L and venetoclax (15.5%), idelalisib + rituximab (6.9%), bendamustine + rituximab (3.5%), and venetoclax + rituximab (3.5%) in 2L. This study expands the information available on patients with CLL in Spain, describing the diversity in patient characteristics and therapeutic approaches in clinical practice.
This study was founded by AstraZeneca Farmacéutica Spain, S.A.
Article
Published version
English
Leucèmia limfocítica crònica - Tractament; Tractament del llenguatge natural (Informàtica); Històries clíniques - Informàtica; DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia, Lymphoid::Leukemia, B-Cell::Leukemia, Lymphocytic, Chronic, B-Cell; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Records::Medical Records::Medical Records Systems, Computerized::Electronic Health Records; INFORMATION SCIENCE::Information Science::Computing Methodologies::Algorithms::Artificial Intelligence::Natural Language Processing; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::leucemia linfoide::leucemia de células B::leucemia linfocítica crónica de células B; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros médicos::sistemas informatizados de historias clínicas::historias clínicas electrónicas; CIENCIA DE LA INFORMACIÓN::Ciencias de la información::metodologías computacionales::algoritmos::inteligencia artificial::procesamiento del lenguaje natural
MDPI
Cancers;15(16)
https://doi.org/10.3390/cancers15164047
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3396]
